Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Cancer: early-phase trial registry
279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #6 of 28,707 conditions by registered trial count.
621 US clinical trials · 279 currently recruiting · #6 of 28,707 conditions by registered trial count
Cancer: 621 US clinical trials tracked, 279 recruiting.
Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.
Enrollment posture brief
Registry condition cancer
OPEN 279 | RECR 45% | LATE 31 | EARLY 164 | RANK #6 | SPON 31
Volume-matched condition peers
Nearest open-share peer: Duchenne Muscular Dystrophy (45% recruiting · 49 trials)
Cancer lists 279 open slots (45% of 621 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Cancer is recruiting above its size-band peers.
279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.
-
Typical Cancer enrolment sits around 108 participants.
Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.
-
Cancer research is mostly interventional.
462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
621 total, page 11 of 13
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00357084
Tobacco Treatment Comparison for Cancer Care
University of Wisconsin, Madison
NCT06218823
Body Composition Post Cancer Treatment
Prisma Health-Upstate
NCT03690401
Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors
University of Maryland, Baltimore
NCT05499663
Body Composition During Cancer Treatment
Prisma Health-Upstate
NCT03784911
Development of Calm for Cancer Prototype Mobile App
Calm.com
NCT05459168
ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Advaxis
NCT02325557
Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors
CanBas Co.
NCT00551512
The Families Addressing Cancer Together Intervention for Parents With Cancer
UNC Lineberger Comprehensive Cancer Center
NCT05377749
eMOTION Formative Study
University of Southern California
NCT06125964
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Connecticut Children's Medical Center
NCT04036032
Phase I Study of TAS-106 in Combo With Carboplatin
M.D. Anderson Cancer Center
NCT00752011
The Effect of Walking on Fatigue After Chemotherapy in Patients 65 and Older
UNC Lineberger Comprehensive Cancer Center
NCT02191982
Microbiome in Lung Cancer and Other Malignancies
Taher Abu Hejleh
NCT03688347
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Esanex
NCT00506805
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America
NCT02482168
VIDeOS for Smoking Cessation
Medical University of South Carolina
NCT06307496
Oral Administration of STC-15 in Subjects With Advanced Malignancies
STORM Therapeutics
NCT05584111
Safety and Pharmacokinetics of XL647 Administered Orally to Subjects With Solid Tumors
Kadmon Corporation
NCT00086528
IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial
The University of Texas Medical Branch, Galveston
NCT01869348
A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer
R-Pharm
NCT00422097
STEP AND GO: A Study of Technology-based Exercise Promotion
The University of Texas Medical Branch, Galveston
NCT01953224
Study of NK012 in Patients With Refractory Solid Tumors
Nippon Kayaku Co.
NCT00542958
Biomarker Feedback to Motivate Tobacco Cessation in Pregnant ALaska Native Women: Phase 2
Mayo Clinic
NCT02018640
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT00437372
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
University of Pittsburgh
NCT00226239
Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)
Cephalon
NCT00236041
Digital Symptom Tracking, Patient Engagement and Quality of Life in GI Oncology Clinic Patients
Duke University
NCT03459352
Study for the Liquid Chromatography-mass Spectrometry (LC-MS/MS) Assessment of Oxidative DNA Damage in Relation to Antioxidant Usage
Roswell Park Cancer Institute
NCT01038024
Communicating About Sexual Concerns and Dysfunction Effectively (CASCADE) Program
Duke University
NCT03658161
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients
Pfizer
NCT00927823
A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors
Novartis Pharmaceuticals
NCT00570284
A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia
Kartos Therapeutics
NCT02016729
Feasibility and Utilization of an Application-based Question Prompt List
Barbara Ann Karmanos Cancer Institute
NCT03676920
Human Tumor Sequencing Project
Scripps Translational Science Institute
NCT01608230
Tailored Home-Based Exercise Program for Multiple Chronic Conditions
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03874754
Supportive Care Delivered by Telemedicine to Cancer Patients at Home
Memorial Sloan Kettering Cancer Center
NCT04136340
SmartManage Stress Management for HIV+ Cancer Survivors
University of Miami
NCT04544917
A Phase 1 Study of ARQ 197 in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
NCT00612703
Study of XL647 Administered Orally Daily to Patients With Solid Tumors
Kadmon Corporation
NCT00336765
Emerging From the Haze™- Measuring the Impact of a Psycho-education Program on Perceived Cognition After Breast Cancer Treatment
Cedars-Sinai Medical Center
NCT02360917
Lymphedema Sensor Technology Development Study
Northwestern University
NCT06778837
Proactive Psychiatry Consultation for Patients With Cancer and Severe Mental Illness
Massachusetts General Hospital
NCT02594696
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
Fred Hutchinson Cancer Center
NCT00002673
Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's Lymphoma
Novartis Pharmaceuticals
NCT01691807
Improving Symptom Self-management in Adolescents & Young Adults With Cancer
Virginia Commonwealth University
NCT02974569
A Trial of PDL192 in Subjects With Advanced Solid Tumors
Abbott
NCT00738764
Emotion Regulation and Cancer Caregiving
Stanford University
NCT06123416
Vinorelbine and XR9576 to Treat Cancer
National Cancer Institute (NCI)
NCT00001944
Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
University of Alabama at Birmingham
NCT00581971
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 116 |
| Phase 2 | 48 |
| Phase 3 | 27 |
| Phase 4 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Cancer page
621 registered trials, 279 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 279 Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cancer condition card totals 621 registered trials; most-linked intervention Usual Care; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.